Nuvation has a best-in-class lung cancer drug that could be approved in the US in June. Read why I'm bullish on the stock ...
Henry Gosebruch, Neumora’s CEO since 2023, will depart. Elsewhere, Biogen dropped two antisense drugs in a pipeline cull and Voyager hit a setback for its ALS gene therapy.
A Boston VC firm is launching a new neuroscience company with a $93M investment that aims to treat disorders including ...
PureTech Founded Entity Seaport Therapeutics Announces Publication of New Research Demonstrating Increased Lymphatic Transport with Glyph Platform ...
Seaport Therapeutics (“Seaport” or the “Company”), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the ...
BOSTON - Seaport Therapeutics, a clinical-stage biopharmaceutical company, has published new research demonstrating significant advancements in drug delivery through the lymphatic system using its ...
AbbVie and Xilio Therapeutics, Inc. , a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for ...
Kenai Therapeutics, a biotechnology company leveraging induced pluripotent stem cell (iPSC) technology to discover and develop a platform of off-the-shelf neuron replacement therapies for neurological ...
The acquisition of Anthos Therapeutics could be worth up to $3.1 billion and returns to Novartis a blood thinner it licensed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback